In the Clinic for May 11, 2026
BioWorld’s May 11, 2026 “In the Clinic” roundup aggregates the day’s most relevant biopharma and med‑tech snapshots, special reports, and infographics. The page links to data‑driven analyses covering topics from mRNA vaccine research and China’s GLP‑1 landscape to pulsed‑field ablation for atrial fibrillation. It also provides annual performance reviews of BioWorld’s 2025 coverage across biopharma, med‑tech, and science. The collection serves as a one‑stop hub for industry executives seeking quick access to the latest developments.
BioWorld and Nasdaq Stock Indices
BioWorld’s May briefs highlight three distinct biotech developments. Researchers at the La Jolla Institute for Immunology have isolated human antibodies that neutralize measles by blocking viral entry, a timely advance as global measles vaccination rates slip. Meanwhile, eight confirmed hantavirus...
Financings for May 6, 2026
UK‑based Cytospire Therapeutics announced a £61 million (≈$82.7 million) Series A round to accelerate its EGFR‑targeted T‑cell engager pipeline for solid tumours. The capital backs multiple pre‑clinical programs and reflects strong investor confidence in next‑generation immunotherapies. Bio Korea 2026 highlighted a shift in...
Regulatory Actions for May 6, 2026
On May 6, 2026, a regulatory roundup highlighted several biopharma and medical‑technology firms achieving pivotal milestones. Clear Scientific secured an FDA Breakthrough Therapy designation for its gene‑editing platform, while Fate received EMA approval for its late‑stage oncology drug. Multi4, Neurocare, Opus Genetics...
In the Clinic for May 6, 2026
The May 6, 2026 clinic roundup collates the latest clinical data readouts and peer‑reviewed publications from a cross‑section of biopharma and med‑tech firms. Companies such as Cellectar, Cytokinetics, Earlydiagnostics, Eli Lilly, Eupraxia, J&J, Ocugen, Palisade, Regeneron, Sanofi, Telix and Viridian disclosed trial outcomes...
Other News to Note for May 6, 2026
Cytospire Therapeutics announced a £61 million (≈$82.7 million) Series A round to advance its next‑generation T‑cell engager platform targeting the epidermal growth factor receptor (EGFR) in solid tumours. The funding will accelerate pre‑clinical and early‑clinical programs aimed at delivering more selective immunotherapies. Meanwhile,...
Bio Korea 2026 Kicks Off with Spotlight on Oligonucleotides
In early May 2026, several biotech firms announced pivotal milestones. Axsome Therapeutics received FDA clearance for Auvelity (AXS‑05) to treat agitation in Alzheimer’s disease, a condition affecting up to 75% of patients. Sonire Therapeutics began its U.S. Sunrise II trial of...
Regulatory Actions for May 1, 2026
BioWorld released a comprehensive “Regulatory Actions for May 1, 2026” roundup, collating FDA, EMA and other global regulator updates across biopharma, medical technology, and policy domains. The collection links to data snapshots, infographics on digital analysis, and special reports covering topics such...
Other News to Note for April 30, 2026
Chinese biotech companies have reached an inflection point, gaining leverage as co‑dealmakers in cross‑border partnerships, according to multinational executives. Roche announced the discovery of new TREM2 agonist compounds aimed at modulating microglial activity for neurodegenerative diseases. Plasticity launched an advanced...
Regulatory Actions for April 30, 2026
Regulatory updates released on April 30, 2026 highlight a wave of approvals and submissions across biopharma and med‑tech firms. Gilead secured FDA clearance for a next‑generation hepatitis treatment, while Dr. Reddy's obtained EMA approval for a generic oncology product. 3D...
Regulatory Actions for April 28, 2026
Regulatory snapshots released on April 28, 2026 detail a wave of approvals, submissions and designations across leading biopharma and med‑tech firms. Companies such as Arcutis, AstraZeneca, GSK, Intellia and Novartis announced FDA, EMA or WHO milestones for products ranging from...
Biopharma Money Raised: Jan. 1-April 23, 2026
Regeneron’s Otarmeni, a gene‑therapy for congenital hearing loss, earned FDA accelerated approval and will be provided free of charge, marking a rare zero‑cost gene‑therapy launch. At AACR 2026, researchers highlighted breakthroughs in minimal residual disease (MRD) detection that sharpen relapse...
Regulatory Actions for April 24, 2026
On April 24, 2026, regulators across the U.S., Europe, and WHO announced several key decisions affecting leading biopharma and med‑tech firms. Biotronik received FDA clearance for a next‑generation cardiac pacing system, while Clearpoint Neuro earned a CE mark for its...
Pfizer Presents Auristatin S ADC for GPNMB Tumors
Pfizer has unveiled PF-08046033, an antibody‑drug conjugate that links the potent cytotoxic agent auristatin S to an antibody targeting the transmembrane glycoprotein NMB (GPNMB). The ADC is designed to deliver the payload directly into GPNMB‑expressing tumors, potentially widening the therapeutic...
Pharma Industry Faces Long Haul to Get Return on Investment From AI
The pharmaceutical sector is confronting a prolonged timeline before artificial intelligence delivers a clear return on investment. While AI tools have accelerated early‑stage drug discovery, most companies still grapple with data integration, regulatory compliance, and the high cost of talent....
In the Clinic for April 22, 2026
The April 22, 2026 clinic roundup collated the latest clinical data and peer‑reviewed publications from a cross‑section of biopharma and med‑tech firms. Companies such as AB Science, AstraZeneca, Bioage, Eisai, Eupraxia, Invera, Ionis, Livanova, Lytix, Merck, Reva and Scandinavian Real Heart disclosed trial...
Neolaia Synthesizes New CD38 Inhibitors
Biohaven disclosed detailed preclinical data on BHV‑2100, a TRPM3 calcium‑channel modulator aimed at neuropathic pain. A new meta‑analysis concluded that anti‑amyloid therapies for Alzheimer’s have not demonstrated clinically meaningful benefits, intensifying debate over the approach. Jiangsu and Shanghai Hengrui patented...
Incyte Discloses New TYK2 And/Or JAK1 Inhibitors
Incyte announced the discovery of a new series of small‑molecule inhibitors that selectively target TYK2 and JAK1, two kinases central to cytokine signaling in autoimmune disorders. The compounds demonstrated sub‑nanomolar potency in cell‑based assays and favorable safety margins in early...
Biopharma Money Raised: Jan. 1-April 16, 2026
BioWorld’s April 17 briefing highlights three pivotal biotech developments. A new meta‑analysis concludes that anti‑amyloid Alzheimer’s drugs have not demonstrated clinically meaningful benefits, intensifying debate over the therapeutic class. Researchers disclosed a selective CBL‑B inhibitor with an improved safety profile,...
Regulatory Actions for April 17, 2026
On April 17, 2026 regulators issued a series of approvals, clearances and designations across the biopharma and medical‑technology sectors. Companies such as Adimab, Aicuris, Bavarian Nordic, Royal Philips and Savara were highlighted for FDA, EMA, WHO and CE‑mark actions. The...
Regulatory Actions for April 16, 2026
BioWorld’s April 16, 2026 regulatory snapshot lists a flurry of biopharma and med‑tech actions, ranging from new drug submissions to market approvals and designations. Companies such as Airs, Aligos, AOP, Arbutus, Cala, Dogwood, Immutep, Leadiant, Northstar, Opna, Reach Surgical, Waters and Xspray...
In the Clinic for April 14, 2026
The "In the clinic for April 14, 2026" page serves as a centralized hub that aggregates the latest Bioworld data snapshots, special reports, and infographics across biopharma, medical technology, and emerging therapeutic areas. It links to analyses on mRNA vaccine...
Stryker Agrees to Buy Amplitude Vascular Systems for IVL Tech
Stryker announced a definitive agreement to acquire Amplitude Vascular Systems, a specialist in intravascular lithotripsy (IVL) technology, for roughly $1.5 billion in cash. The deal broadens Stryker’s cardiovascular portfolio by adding a catheter platform designed for treating heavily calcified coronary lesions,...
CMS Looks to Bring Rx Prior Authorization Into Digital Age
The Centers for Medicare & Medicaid Services (CMS) announced a push to digitize prescription‑drug prior authorization (PA) through electronic prior authorization (ePA) standards. The initiative mandates health plans and pharmacies to adopt interoperable, real‑time PA workflows by the end of...
Appointments and Advancements for April 13, 2026
On April 13, 2026 three biotech firms filed patents on novel drug candidates. Accure Therapeutics disclosed oligopeptide derivatives that inhibit matrix metalloproteinases MMP‑2 and MMP‑9, enzymes linked to cancer invasion and fibrosis. Merck Sharp & Dohme (MSD) introduced indazole‑based blockers of HCN1/2...
Appointments and Advancements for April 10, 2026
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 blockers that alleviate inflammatory and neuropathic pain in rodents without notable cardiovascular effects. Parallel research reveals chronic inflammation in the bone‑marrow niche drives hematopoietic stem cells toward pre‑leukemic clones via cytokines such...
Other News to Note for April 10, 2026
BioWorld’s April 10 briefing highlights three notable developments. Jiangsu and Shanghai Hengrui have patented novel Nav1.8 sodium‑channel blockers, a class of compounds with potential for pain and inflammatory disease therapies. New hematopoietic stem‑cell research links chronic inflammation to early‑stage leukemia, deepening...
Regulatory Actions for April 9, 2026
On April 9, 2026 regulators issued a batch of approvals and designations across biopharma and medical‑technology firms. Anumana secured FDA clearance for its AI‑driven diagnostic platform, while Bausch + Lomb obtained EU approval for a new ocular therapy. Becton Dickinson earned a CE mark for...
VC Activity Drives March Med-Tech Financings to $2.4B
In March, the med‑tech sector highlighted three breakthrough programs that attracted venture capital attention. Jiangsu and Shanghai Hengrui patented selective Nav1.8 sodium‑channel blockers and plan IND‑enabling toxicology this year, targeting chronic pain with a Phase I start in 2027. New single‑cell...
Appointments and Advancements for April 7, 2026
On April 7, 2026, BioWorld reported three notable biotech developments. Jiangsu and Shanghai Hengrui patented novel Nav1.8 sodium‑channel blockers, a potential new class for chronic pain management. Researchers highlighted hematopoietic stem‑cell studies that implicate inflammation as an early driver of...
Regulatory Actions for April 7, 2026
On April 7, 2026 regulators issued several high‑profile decisions across biopharma and medical‑technology. Allevion secured FDA clearance for its next‑generation gene‑therapy platform, Regeneron obtained EMA approval for a monoclonal antibody targeting a rare autoimmune disorder, and Stereotaxis earned a CE...
Kennedy Sidestepping Court Order Sidelining ACIP?
BioWorld’s April 7 briefing highlights three notable developments: Jiangsu and Shanghai Hengrui have patented a new class of Nav1.8 sodium‑channel blockers aimed at chronic pain treatment; recent hematopoietic stem‑cell research underscores inflammation’s role in initiating leukemia; and Infinimmune presented preclinical data...
South Korea Streamlines Biosimilar Review, Clinical Trials
BioWorld Asia’s April 7 2026 briefing highlighted three emerging biotech developments. Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that deliver strong analgesic effects with minimal off‑target activity, positioning them as potential first‑in‑class chronic pain therapies. New research linked chronic inflammation in...
Gilead Buying Tubulis and Its ADCs in $5B Takeover Bid
BioWorld’s April 7 briefing spotlights three notable biotech developments. Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that deliver strong analgesic effects with minimal off‑target activity, opening a potential new class for chronic pain. Parallel studies reveal...
Sononeu Wins $5.2M ARPA-H Grant for Ultrasound-Activated Therapeutics
Sononeu, a Boston‑based biotech, secured a $5.2 million grant from the U.S. Advanced Research Projects Agency for Health (ARPA‑H) to advance its ultrasound‑activated therapeutic platform. The award will fund pre‑clinical development of drug‑delivery systems that release payloads only when exposed to...
Amplia Halts Enrollment in Phase II Pancreatic Cancer Trial
Amplia Therapeutics announced it is halting enrollment in its phase II trial of the investigational pancreatic cancer agent after an interim safety review revealed concerning signals and modest efficacy. The study, which began enrolling patients in early 2025, was designed to...
Other News to Note for April 7, 2026
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented novel Nav1.8 sodium‑channel blockers that selectively target pain signaling, showing strong pre‑clinical analgesic activity with minimal off‑target effects. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, creating a microenvironment that...
In the Clinic for April 7, 2026
BioWorld’s April 7, 2026 clinic roundup compiles a broad set of data snapshots, special reports and infographics spanning biopharma, medical technology, and emerging therapeutic areas. The collection links to analyses on M&A activity, GLP‑1 developments in China, mRNA vaccine research, pulsed‑field ablation...
Best of BioWorld: Q1
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that show potent analgesic activity with minimal off‑target effects, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes hematopoietic stem cells, fostering early...
Financings for April 7, 2026
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without motor side effects, and plan IND‑enabling studies later this year. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, fostering leukemic...
Sector Tariff Now More than a Threat – for some Rx Companies
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 blockers that demonstrate potent pre‑clinical analgesic activity for chronic neuropathic pain. New research links chronic inflammatory signaling to early leukemic transformation in hematopoietic stem cells, suggesting anti‑inflammatory approaches could intervene before disease...
Biopharma Financings Nearly Double Vs. 2025 to $25.1B
Biopharma financing in 2026 surged to $25.1 billion, almost twice the amount raised in 2025. The jump reflects a wave of venture‑capital commitments, a robust IPO market, and heightened merger‑and‑acquisition activity. Public offerings alone added roughly $8 billion, while private rounds supplied...
Five-Drug VIPOR Regimen Shows Promise in Aggressive Blood Cancer
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without cardiac or CNS effects, and plan IND‑enabling toxicology studies in 2026 with Phase I trials slated for 2027. Parallel advances in hematopoietic...
Hematopoietic Stem Cell Research Points to Leukemia’s Early Roots
Recent hematopoietic stem cell (HSC) studies reveal that chronic inflammation can seed the earliest genetic lesions that later evolve into leukemia. The research shows that inflammatory signals remodel the bone‑marrow niche, prompting mutations in primitive stem cells long before clinical...
Stipple Launches with $100M for Novel Oncology Targets
Stipple, a new biotech focused on oncology, announced a $100 million Series A financing round to pursue novel, historically undruggable cancer targets. The round was led by top‑tier venture firms and includes strategic commitments from several large pharmaceutical partners. Stipple’s founding team...
Optimization of Brain-Permeable SGK1 Inhibitors for Neurodegenerative Diseases
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that alleviate inflammatory and neuropathic pain in rodent studies and are slated for IND‑enabling toxicology this year, aiming for Phase I trials in 2027. Parallel research highlights chronic inflammation’s role...
Dectisomes Show Potent Activity Against High-Priority Fungal Pathogens
Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that show potent analgesic effects with minimal off‑target activity. New research links chronic inflammation in the bone‑marrow niche to epigenetic reprogramming of hematopoietic stem cells, suggesting early‑intervention strategies for leukemia prevention. Infinimmune...
Orexin OX2 Receptor Agonists Disclosed in Vertex Pharmaceuticals Patent
Vertex Pharmaceuticals has filed a patent covering a new series of orexin OX2‑receptor agonists, marking the company’s first public foray into sleep‑modulating therapeutics. The disclosed molecules feature distinct heterocyclic cores and enhanced blood‑brain barrier penetration, aiming for improved potency and...
Nrf2 Activator Counteracts Atopic Dermatitis Pathology
Researchers have identified a novel Nrf2 activator that mitigates key pathological features of atopic dermatitis in preclinical studies. The compound suppresses oxidative stress and downregulates pro‑inflammatory cytokines, leading to restored skin barrier integrity in murine models. Data presented at the...
New LRH-1 Antagonists Exhibit Antitumor Activity in Prostate Cancer Models
Researchers have identified a new class of liver receptor homolog‑1 (LRH‑1) antagonists that demonstrate potent antitumor activity in preclinical prostate cancer models. In mouse xenografts, oral administration of the compounds reduced tumor volume by up to 65% without notable adverse...